secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001193125-25-028641
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO Preetam Shah departs; Frank Karbe appointed as new CFO effective Feb 24, 2025
--------------------------------------------------------------------------------

- CFO Preetam Shah to separate on Feb 24, 2025; receives 9 months’ salary, 2024 bonus, and 15 months’ COBRA.
- Shah will consult for six months with continued equity vesting during consulting period.
- Frank Karbe named CFO effective Feb 24; previously CEO of Better Therapeutics and CFO of Myovant Sciences.
- Karbe’s base salary $525K, target bonus 40%, signing bonus $50K; options for 115K shares and RSUs for 57.5K shares.
- Severance for Karbe: 9 months’ salary without cause/resignation for good reason; 12 months with change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/0001193125-25-028641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/d928043d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-028641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer